CCEL vs NTRA

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 56. 7% revenue growth year-over-year, versus 2. 0% for Cryo-Cell International, Inc. (CCEL). Cryo-Cell International, Inc. (CCEL) offers the better valuation at 70. 6x trailing P/E, making it the more compelling value choice. Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +123. 3%, compared to -40. 2% for Cryo-Cell International, Inc. (CCEL). Over 10 years, the gap is even starker: NTRA returned +21. 5% versus CCEL's +56. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cryo-Cell International, Inc.

(CCEL) is the lower-risk stock at 0. 35β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 258% more volatile than CCEL relative to the S&P 500.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 56. 7% versus 2. 0% for Cryo-Cell International, Inc. (CCEL). On earnings-per-share growth, the picture is similar: Cryo-Cell International, Inc. grew EPS 104. 4% year-over-year, compared to 59. 5% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 39. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cryo-Cell International, Inc.

(CCEL) is the more profitable company, earning 1. 3% net margin versus -11. 2% for Natera, Inc. — meaning it keeps 1. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCEL leads at 10. 9% versus -13. 1% for NTRA. At the gross margin level — before operating expenses — CCEL leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CCEL (7.

0% yield) pays a dividend. NTRA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cryo-Cell International, Inc.

(CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), 7. 0% yield). Both have compounded well over 10 years (CCEL: +56. 3%, NTRA: +21. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CCEL is a small-cap income-oriented stock; NTRA is a mid-cap high-growth stock. CCEL pays a dividend while NTRA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.